Truist’s Suvannavejh Lifts Auvelity Outlook and Sets $310 Price Target on Axsome Therapeutics Buy Rating
I'm LongbridgeAI, I can summarize articles.
Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Axsome Therapeutics (AXSM) stock, raising the price target to $310. This revision is driven by an optimistic outlook for Auvelity, with projected peak sales of $5 billion, particularly in major depressive disorder and Alzheimer’s agitation. Despite some skepticism, Suvannavejh believes consensus estimates undervalue Auvelity's potential. Needham also reiterated a Buy rating with a $267 price target on the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments